Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% from the United States Food and Drug Administration (FDA) to market a generic equivalent of Taro Pharmaceuticals North America, Inc’s Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc’s (collectively Taro) Topicort® Cream, 0.25%.

Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% are the AB rated generic equivalent of Taro’s Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%. Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort® LP emollient Cream had US sales of USD 33 million (IMS MAT September 2016) while Topicort® Cream had US sales of USD 17 million (IMS MAT September 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5^th and the 6^th largest generics pharmaceutical company by market capitalization (December 31^st, 2016, Bloomberg) and sales globally (September 30^th, 2016, Bloomberg). The Company is the 5^th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3^rd largest Indian pharmaceutical company by revenues; the 6^th largest generic pharmaceutical player in Japan and the 4^th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31^st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Shamsher Gorawara
Head – Corporate Communications
Ph: +91-98 20 338 555
Email: shamshergorawara@lupin.com

or

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Email: arvindbothra@lupin.com 

*Safe Harbor Statement

Topicort® is the registered trademark of Taro Pharmaceuticals USA, Inc. and or its affiliates.